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Abstract 81 
Aim: Polycystic ovary syndrome (PCOS) is a common endocrine-metabolic disorder. 82 
It affects women’s physical well-being and leads to great psychological distress. 83 
Indeed, women with PCOS show a compromised quality of life as well as impaired 84 
emotional well-being. The aim of the present study is to assess personality 85 
characteristics, body image, and alexithymia in women with PCOS. Materials and 86 
Methods: 59 women with PCOS and 38 healthy controls were administered the 87 
Toronto Alexithymia Scale, the Body Uneasiness Test, and the Minnesota 88 
Multiphasic Personality Inventory-2. Results: The PCOS group showed higher values 89 
of alexithymia and a higher body uneasiness. They also showed higher values on 90 
many Clinical, Content, and Supplementary scales of the Minnesota Multiphasic 91 
Personality Inventory-2. Discussion: It seems that physical appearance and bodily 92 
function have a central place in the minds of women with PCOS, as well as in their 93 
relationships. However, it is a body they find it hard to feel and with which they 94 
mostly feel uncomfortable. Their approach to the outside world seems to be 95 
characterized by a certain degree of immaturity, anger, hostility, and distrust. Low 96 
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self-esteem also seems to be connected to a certain tendency toward introversion and 97 
withdrawal. This leads to problems in social, professional, and intimate relationships. 98 
 99 






1. Introduction 104 
Polycystic ovary syndrome (PCOS) is a common endocrine-metabolic disorder 105 
affecting reproductive-age women. Its estimated prevalence ranges from 5% to 10% 106 
of adult female population [1-3], but can be up to 20% depending on the diagnostic 107 
criteria used [4]. The National Institute of Health criteria include only 108 
hyperandrogenism and anovulation [5], whereas the Rotterdam consensus workshop 109 
of the European Society for Human Reproduction and Embryology/American 110 
Society for Reproductive Medicine added as a third criterion the ultrasonographic 111 
evidence of polycystic ovaries, stating that any 2 of the 3 criteria are sufficient for 112 
diagnosis [6]. This leads to an increased prevalence of the syndrome [7].  113 
Symptoms include anovulation, irregular menstrual cycles, micropolycystic 114 
ovaries and clinical and/or biochemical hyperandrogenism (e.g., hirsutism, acne, 115 
alopecia) [8-10]. PCOS is also associated with obesity, and it is the leading cause of 116 
female infertility [11]. Long-term health risks associated with PCOS include type 2 117 
diabetes [12,13], uterine and endometrial cancer [14,15], irritable bowel syndrome 118 
[16], thyroid disorders [17,18], and metabolic disturbances (i.e., cardiovascular disease 119 
[19], dyslipidemia, and hypertension [15,20]).  120 
The causes of PCOS are still unknown, although some studies suggest that a 121 
combination of insulin resistance and an increase in androgens contribute to its 122 
development [21], as well as genetics [22,23]. 123 
PCOS affects women’s physical well-being and leads to great psychological 124 
distress, compromising their quality of life [24-26]. It was found to be co-morbid 125 
with several mental disorders (Table 1). Depending on the disorder and the criteria 126 
used for the assessment, its comorbidity with mood disorders ranges from 18.2% to 127 
81%, while its comorbidity with anxiety disorders ranges from 2.8% to 35.7% [27-128 
34]. Women with PCOS not only seem to be more depressed than controls, but their 129 
level of depression tends to be more severe [31-33]. Studies have shown that PCOS 130 
seems to be comorbid with other mental disorders such as bipolar and posttraumatic 131 
stress disorders, somatization, and obsessive–compulsive functioning [35,36]. 132 
Moreover, women with PCOS are approximately twice as likely to be hospitalized for 133 
stress, anxiety, depression, illicit drug use, and self-harm behaviors [37]. 134 
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The low level of quality of life in women with PCOS has been related to 135 
anxiety and depression. However, it is difficult to determine whether depression 136 
and/or anxiety influence lower perceived quality of life or whether poor perception 137 
of quality of life increases depression and/or anxiety [27]. 138 
It has also been suggested that PCOS symptoms contribute to decreasing 139 
women’s quality of life [38,39]. Hirsutism, acne, and obesity deeply undermine 140 
women’s self-esteem, self-image, and self-worth due to a lower perception of the 141 
feminine identity, with a great impact on their social life as well as intimate and sexual 142 
relationships [40-42]. Body image is also compromised by infertility and sterility, and 143 
the pressure that women with PCOS feel to have children early in life has been 144 
identified as an additional source of stress [33,43]. 145 
The relationship between PCOS and psychological distress, psychiatric 146 
disorders, and quality of life has been extensively studied, as well as the body image 147 
of women with PCOS. However, psychological aspects such as personality, 148 
attachment style, and emotion regulation are deeply understudied in relation to this 149 
disorder, even though they have a great importance for the clinical management of 150 
the disease. 151 
Indeed, as far as we know, only two studies have explored the relationship 152 
between PCOS and personality profiles: one through the Rorschach test [44] and one 153 
through the Minnesota Multiphasic Personality Inventory-2 (MMPI-2) [45], 154 
underlining that patients with PCOS show higher rates of clinical elevations on 155 
depression, hysteria, psychasthenia, and hypomania, as well as higher absolute scores 156 
on the same scales.  157 
Only one study has investigated emotion regulation strategies in women with 158 
PCOS [46], and no study has investigated attachment related to this syndrome. 159 
The overall rationale of our study was to assess (1a) personality 160 
characteristics, (1b) emotional awareness, (1c) emotion regulation strategies, (1d) 161 
attachment, and (1e) body image in a group of women with PCOS by comparing 162 
them to a control group of healthy women. At the same time, we wanted to explore 163 
(2a) whether psychological variables such as attachment, emotion dysregulation and 164 
body uneasiness were associated with an impaired quality of life, and (2b) whether 165 
such associations differ in women with PCOS and in the controls. 166 
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We hypothesized that compared to controls, women with PCOS are 167 
characterized by (1a) more dysfunctional personality characteristics, (1b) lower 168 
emotional awareness, (1c) more dysfunctional emotion regulation strategies, (1d) 169 
more insecure attachment, and (1e) worse body image. We also hypothesized that 170 
(2a) emotion dysregulation, insecure attachment, and body uneasiness are connected 171 
to a lower quality of life, and that (2b) the association between quality of life and 172 
psychological variables differs between women with PCOS and in the controls, with 173 
a stronger association between physical quality of life, emotion dysregulation, and 174 
insecure attachment in women with PCOS than in the controls. 175 
Since the study has taken into account a number of different variables 176 
concerning psychological functioning in women with PCOS, in the present paper we 177 
would like to focus on hypotheses 1a, 1b, and 1e. Results concerning our other 178 
hypotheses are presented elsewhere [47]. 179 
 180 
2. Materials and Methods 181 
2.1 Participants 182 
We progressively enrolled a convenience sample of 59 outpatients at the two 183 
gynecological endocrinology services of the University Hospital Città della Scienza e 184 
della Salute in Turin. Inclusion criteria for PCOS patients were defined according to 185 
the revised criteria of the Rotterdam Consensus Workshop [6]. As stated before, 186 
these criteria require 2 out of 3 between oligo- and/or anovulation, clinical and/or 187 
biochemical signs of hyperandrogenism and polycystic ovaries, with the exclusion of 188 
other etiologies. Oligomenorrhoea was defined as an interval between two 189 
menstruations of at least 35 days, whereas amenorrhoea was defined as the absence 190 
of vaginal bleeding for at least 3 months. Data on menstrual patterns were self-191 
reported. Clinical hyperandrogenism was defined as the presence of hirsutism 192 
(Ferriman-Gallwey total score > 5), acne, and/or androgenic alopecia. Biochemical 193 
hyperandrogenism was determined by total testosterone, dehydroepiandrosterone 194 
(DHEAS), and sex hormone-binding globulin (SHBG) on fasting blood samples. 195 
Women with other causes of androgen excess or related disorders, such as congenital 196 
adrenal hyperplasia, Cushing syndrome, or an androgen-secreting tumor were 197 
excluded. All the patients underwent a transvaginal ultrasonography to assess ovarian 198 
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morphology. Polycystic ovarian morphology was diagnosed according to the 199 
presence of 12 or more follicles in each ovary measuring 2–9 mm in diameter and/or 200 
the presence of increased ovarian volume (>10 ml) in 1 or both ovaries [48].  201 
The control group of 38 healthy age-matched women was enrolled through local 202 
general practitioners. Inclusion criteria for the control group were (1) absence of 203 
severe gynecological diseases and (2) history of a regular menstrual cycle. 204 
Exclusion criteria for both the PCOS and the control groups were (1) having a poor 205 
knowledge of the Italian language, (2) having a certified psychiatric diagnosis, (3) 206 
having a certified diagnosis of a neurogenerative disease (i.e., Alzheimer disease, 207 
Parkinson disease, etc.), (4) having a certified medical disease,(5) being pregnant, (6) 208 
having been in psychiatric or psychological therapy in the last 6 months. Criterion 1 209 
was set in order to ensure a correct understanding of the questionnaires; Criteria 2-6 210 
were set in order to exclude the influence of other psychological, neurological, or 211 
physical variables on our data. 212 
 213 
2.2 Ethical approval 214 
The study protocol was approved by the Hospital Ethical Committee. All 215 
participants were given a complete description of the study and gave informed 216 
written consent before entering the study. All research procedures were conducted in 217 
accordance with the ethical standards of the committees responsible for human 218 
experimentation (institutional and national) and with the Helsinki Declaration of 219 
1975, as revised in 2000.  220 
 221 
2.3 Measures 222 
This research is part of a wider study aimed at assessing psychological variables in 223 
women with PCOS compared to a control group [47]. The complete study included 224 
the administration of the Short-Form Health Survey (SF-36), the Attachment Style 225 
Questionnaire (ASQ), the Difficulties in Emotion Regulation Scale (DERS), the 226 
Toronto Alexithymia Scale (TAS-20), the Body Uneasiness Test (BUT), and the 227 
MMPI-2. 228 
The administration was conducted at the clinic in the presence of a 229 
psychologist. Because of the number of measures and the number of items in the 230 
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MMPI-2, the questionnaires were completed in two sessions: one in which the 231 
MMPI-2 were administered, and one for the other measures. Half of the sample 232 
completed the MMPI-2 in the first session, and the other half in the second one. The 233 
average time to completion was 84 minutes for the MMPI-2 (range 53-101 minutes) 234 
and 46 minutes for the other questionnaires (range 23-65 minutes). 235 
For the purposes of the present research, we consider only the scores 236 
obtained from the TAS-20, the BUT and the MMPI-2. 237 
The TAS-20 [49,50] is a frequently used 20-item self-reported measure of 238 
alexithymia. The psychometric properties of the scale have been validated across 239 
cultures. A score of ≥61 is considered to be indicative of alexithymia, whereas scores 240 
between 51 and 60 indicate borderline alexithymia. It has a 3-factor structure: 241 
Difficulty in Identifying Feelings (TAS-DIF); Difficulty in Describing Feelings (TAS-242 
DDF), and Externally Oriented Thinking (TAS-EOT). Cronbach’s alpha coefficients 243 
were .89 for TAS-DIF, .83 for TAS-DDF, and .81 for TAS-EOT. 244 
The BUT [51] is a 71-item self-administered questionnaire for the clinical 245 
assessment of body image disorders and related psychopathologies. It consists of 2 246 
different scales: the BUT-A is a 34-item scale assessing body shape, weight 247 
dissatisfaction, avoidance, compulsive control behaviors, detachment, and 248 
estrangement feelings towards one’s own body; the BUT-B is a 37-item scale 249 
assessing specific worries about particular body parts, shapes, or functions such as 250 
buttocks, odor, blushing. For the purpose of this study, analyses were performed on 251 
the Global Severity Index (BUT-GSI), which is computed as the average of the 252 
scores observed on the 34 items comprising the BUT-A section, and the Positive 253 
Symptom Total Index (BUT-PST), which represents the total number of BUT-B 254 
items rated higher than zero. In this study, the internal consistency reliability 255 
coefficients were .91 for the BUT-A and .88 for the BUT-B. 256 
The MMPI-2 [52,53] is a standardized psycho-diagnostic instrument that 257 
consists in 567 dichotomous questions (true or false) designed to provide 258 
psychopathological information in different scales: 3 Validity Scales, 10 Clinical 259 
Scales, 16 Supplementary Scales, and 15 Content Scales. The results on the MMPI-2 260 
test are expressed in standardized t scores. Thus, a scale score is considered indicative 261 
of psychological dysfunction when the t value is ≥65. We dichotomously classified 262 
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each individual in terms of whether or not each scale was in the clinically elevated 263 
range. The internal consistency reliability coefficients in our sample ranged between 264 
.23 and .91 for the Clinical Scales (Masculinity/Femininity vs Social Introversion); 265 
between .72 and .88 for the Content Scales (Type A vs Depression), and between .65 266 
and .91 for the Supplementary Scales (Addiction Potential Scale vs Posttraumatic 267 
Stress Disorder). 268 
 269 
2.4 Statistical Analyses 270 
All statistical analyses were conducted using the Statistical Package for the Social 271 
Sciences (IBM Corp., Armonk, NY, USA) version 24. All tests were 2-tailed, and we 272 
set the statistical significance at p ≤ 0.05. We performed descriptive statistics to 273 
describe demographic and clinical features in the two samples. The existence of 274 
mean differences across the PCOS and control groups on the demographic and 275 
clinical data was investigated using t tests and Pearson Chi-squares. 276 
 277 
3. Results 278 
Descriptive statistics for the demographic and clinical data for the PCOS and the 279 
Control groups are reported in Table 2. As expected, women with PCOS show a 280 
higher mean value on Body Mass Index (BMI; p ≤ 0.000). 281 
Tables 3 to 5 present the clinical data for the PCOS and the control groups. 282 
Concerning the TAS-20 (Table 3), the PCOS group shows higher values than the 283 
control group on the Difficulty in Identifying Feelings scale ( p = 0.025) and in the 284 
Total scale (p = 0.036). On the BUT (Table 4), PCOS patients show higher values 285 
compared to the controls in both the Positive Symptom Total Index (p = 0.015) and 286 
the Global Severity Index (p = 0.002) scales. On the MMPI-2 (Table 5), patients with 287 
PCOS show significantly higher values in the Frequency Validity Scale (p ≤ 0.001) 288 
and lower values in the Defensiveness Scale (p ≤ 0.011). Patients show higher values 289 
in 8 out of 10 Clinical Scales: Hypochondriasis (p ≤ 0.002), Depression (p = 0.001), 290 
Hysteria (p = 0.038), Psychopathic Deviation (p = 0.004), Paranoia (p = 0.011), 291 
Psychasthenia (p = 0.003), Schizophrenia (p = 0.003), and Social Introversion (p = 292 
0.005). On the Content Scales, women with PCOS show higher values on the 293 
following scales: Anxiety (p ≤ 0.001), Fears (p = 0.017), Obsessiveness (p = 0.001), 294 
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Depression (p ≤ 0.001), Health Concerns (p ≤ 0.001), Low Self-Esteem (p = 0.001), 295 
Social Discomfort (p = 0.024), Family Problems (p = 0.002), Work Interference 296 
(55.92 ± 11.23 vs. 48.63 ± 8.05, p ≤ 0.001), and Negative Treatment Indicators (p = 297 
0.001). On Supplementary Scales, PCOS patients show higher values on the 298 
following scales: Back F (p ≤ 0.001), Posttraumatic Stress Disorder (p ≤ 0.001), and 299 
Marital Distress (p ≤ 0.026). 300 
As shown in Table 6, PCOS patients have significantly higher percentages of 301 
clinical elevation on the following scales: Frequency (p = 0.039), Hypochondriasis (p 302 
= 0.032), Depression (p = 0.008), Psychopathic Deviation (p = 0.008), Paranoia (p = 303 
0.030), Schizophrenia (p = 0.005), Anxiety (p = 0.014), Depression (p = 0.003), 304 
Family Problems (p = 0.046), Work Interference (p = 0.012), Posttraumatic Stress 305 
Disorder (p = 0.005), and Marital Distress (p = 0.017). 306 
 307 
4. Discussion 308 
This study is part of more complex research aimed at assessing the psychological 309 
characteristics of women with PCOS compared to a control group of healthy women 310 
and exploring potential correlations between some of these characteristics [47]. 311 
However, with the number of different variables taken into account, in this paper we 312 
chose to focus on the assessment of personality characteristics, emotional awareness, 313 
and body image in the group of women with PCOS compared to controls. It was 314 
hypothesized that women with PCOS exhibit worse body image, lower emotional 315 
awareness, and more dysfunctional personality characteristics. 316 
Results confirm all of our hypotheses. 317 
Consistent with previous literature [1], the present study shows a higher BMI 318 
in women with PCOS. Moreover, results confirm our first hypothesis, indicating that 319 
PCOS patients are characterized by a higher body uneasiness than healthy controls. 320 
Disease-related body appearance (e.g., obesity, hirsutism, and acne) may contribute 321 
to reducing the feminine identity of patients, compromising their body image. 322 
Women with PCOS tend not to see themselves as fitting social and media standards 323 
for body appearance, and this can give rise to depression and impairment in their 324 
emotional well-being.  325 
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Concerning our second hypothesis, a higher overall alexithymia score 326 
emerged as well as a greater difficulty in identifying feelings. From a psychoanalytic 327 
perspective, we can hypothesize that not only do PCOS patients feel unease with 328 
their own bodies—perceived as inadequate, wrong, or somehow bad—but they also 329 
struggle with the subsymbolic messages that arise from their hatred body. In other 330 
words, their difficulties at a somatopsychic level seem to be connected to both the 331 
looking–seeing domain and the feeling–sensing one [47]When it comes to our last 332 
hypothesis, differences emerged in many scales, much more than the ones that were 333 
found statistically significant in the only other study that has investigated the 334 
relationship between PCOS and personality domains through the MMPI-2 [45]. We 335 
found significant differences in the mean scores on Frequency (F) and Defensiveness 336 
(K) Validity Scales. Among Clinical Scales, we found significant differences in the 337 
mean scores of Hypochondriasis (Hs), Depression (D), Hysteria (Hy), Psychopathic 338 
Deviation (Pd), Paranoia (Pa), Psychasthenia (Pt), Schizophrenia (Sc), and Social 339 
Introversion (Si). On the Content Scales, women with PCOS show higher values of 340 
Anxiety (ANX), Fears (FRS), Obsessiveness (OBS), Depression (DEP), Health 341 
Concerns (HEA), Low Self-Esteem (LSE), Social Discomfort (SOD), Family 342 
Problems (FAM), Work Interference (WRK), and Negative Treatment Indicators 343 
(TRT). On Supplementary Scales, PCOS patients show higher values on Back F (Fb), 344 
Posttraumatic Stress Disorder (PK), and Marital Distress Scale (MDS). Moreover, 345 
PCOS patients showed significantly higher percentages of clinical elevation on 346 
Frequency (F), Hypochondriasis (Hs), Depression (D), Psychopathic Deviation (Pd), 347 
Paranoia (Pa), Schizophrenia (Sc), Anxiety (ANX), Depression (DEP), Family 348 
Problems (FAM), Work Interference (WRK), Posttraumatic Stress Disorder (PK), 349 
and Marital Distress (MD). 350 
Women with PCOS seem to experience greater psychological distress (F; Fb) 351 
than healthy controls, as well as fewer defenses against their mental suffering (K), 352 
affecting their internal lives with intense feelings of anguish and despair. 353 
Consistent with previous research [27,30,44], PCOS patients seem to 354 
experience higher levels of anxiety and depression (D, ANX, FRS, DEP).  355 
The relationship between PCOS, anxiety, and depression has been widely 356 
debated. Indeed, many studies support the idea that PCOS clinical facets (e.g. 357 
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obesity, testosterone levels, hirsutism, and menstrual irregularities) may be risk 358 
factors for psychological distress and depression in patients with and without PCOS 359 
[54-57]. However, other studies have pointed out that depression and anxiety are 360 
independent from PCOS symptoms, such as obesity, hirsutism, or acne [30,58]. 361 
From our psychoanalytical perspective, since the perception of self-worth has been 362 
found to influence mood [59,60], it would be interesting to further research the 363 
connection between depression levels and impaired body image. 364 
Scores on the somatic scales (Hs, Hy) were higher in women with PCOS than 365 
in the controls. It seems that body appearance and body functioning have a central 366 
place in the minds of women with PCOS as well as in their relationships. However, it 367 
is a body they find it hard to feel and with which they mostly feel uncomfortable, as 368 
suggested by the results obtained with the BUT.  This, together with alexithymia, can 369 
have a great impact on illness perception [61] and can exacerbate their worries about 370 
their health (HEA).  371 
Women with PCOS show higher levels of posttraumatic symptomatology 372 
(PK). We can assume that living with a gynecological disease can be in itself a 373 
traumatic condition that gives rise to dysregulated emotions. Moreover, traumatic 374 
conditions during development can increase women’s somatopsychic vulnerability 375 
and their risk for physical health problems [62], leading to more dysfunctional 376 
emotion regulation strategies [63,64]. 377 
The constant preoccupation with a body they found it difficult to feel, 378 
together with a distorted body image, can be traced to the root of some obsessions 379 
(Pt, OBS), which could be explained by fixation on the idea that there is something 380 
strange in them they need to fix. This is consistent with previous literature showing 381 
that PCOS patients exhibit an exaggerated introspective behavior that could lead to 382 
pathological self-criticism and ruminative thinking [44].  383 
Moreover, women with PCOS seem to be sometimes immature in dealing 384 
with the external world, so that they cannot pursue their desires and fantasies with 385 
reality-anchored intentionality and fulfilling behaviors (Sc).  386 
Hatred of the body and its limits is often projected on the outside world (Pa), 387 
giving rise to intense anger, hostility, and distrust (Pd; TRT). These results are 388 
consistent with previous research in underlining that women with PCOS seem to use 389 
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more psychic energy than needed, to express their anger outwardly, and to have 390 
difficulty tolerating frustration [65,66].  391 
The result is higher introversion and withdrawal from others (Si), connected 392 
to low self-esteem (LSE) and leading to problems in social, professional, and intimate 393 
relationships (MDS; SOD; FAM; WRK).  394 
These results are consistent with previous research [9,67-69] in underlining 395 
that PCOS strongly impacts the social lives of women, adversely affecting their 396 
leisure time as well as their relationships with their families and friends, mostly 397 
because of their perceived unattractiveness. It also compromises marital 398 
relationships; women with PCOS often indicate lower satisfaction with their sex lives 399 
and a lower perception of their own sexual attractiveness. 400 
 401 
Limitations and clinical implications 402 
This study has some critical limitations. First of all, the generalizability of the results 403 
is limited by our small, Italian-only convenience sample, collected in only one center. 404 
Second, the cross-sectional design does not allow for causal inferences or following 405 
the development of the variables over time. Further longitudinal studies are needed. 406 
Psychological variables were assessed through self-report measures; further studies 407 
should also take into account clinical and observational data. In addition, variables 408 
likely to influence psychological factors, such as hormonal levels, different symptoms 409 
(such as hirsutism, infertility, etc.), or gravity of symptoms were not examined in our 410 
study. Future research should take these aspects into account. 411 
Despite these limitations, the present study gives a more comprehensive 412 
evaluation of the psychological functions of women with PCOS. In particular, it 413 
sheds light on body image, emotional awareness, and specific dysfunctional 414 
personality characteristics in women with PCOS. 415 
These results are of great importance for both psychologists and 416 
gynecologists that take care of PCOS women and may have relevant clinical 417 
implications for planning psychological interventions for this population. 418 
In fact, psychological variables are often inconspicuously and marginally 419 
taken into account in the clinical management of physical disorders such as PCOS. 420 
However, underlining specific dysfunctional psychological profiles in women with 421 
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PCOS highlights the need for integrated health care protocols that also take women’s 422 
mental functioning in to account, in both the assessment and the treatment phase. 423 
Moreover, our preliminary results may help clinicians pay attention to quality 424 
of life, depression, and anxiety in women with PCOS, as well as the personality 425 
characteristics of these women, an aspect that has been widely understudied and 426 
underestimated in previous research and in clinical practice. 427 
This may improve patients’ psychological and physical well-being as well as 428 
their compliance and the quality of the clinical management of the disease [70-72], 429 
benefitting the societal costs of the health care system [73]. 430 
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Current knowledge on the subject. 453 
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• Women with PCOS show impaired emotional well-being (in particular, 454 
anxiety and depression). 455 
• Women with PCOS show body dissatisfaction and compromised quality of 456 
life. 457 
• On the MMPI-2 clinical scales, patients with PCOS show higher rates of 458 
clinical elevations on depression, hysteria, psychasthenia, and hypomania, as 459 
well as higher absolute scores on the same scales. 460 
 461 
What this study adds. 462 
• In our research, women with PCOS seem to be characterized by a 463 
dysfunctional body image and a compromised emotional awareness.  464 
• They show significant differences compared to our sample of healthy women 465 
in the mean scores of many Validity, Clinical, Content, and Supplementary 466 
scales of the MMPI-2. In particular, they seem to have fewer defenses against 467 
mental suffering. Moreover, it seems that body appearance and bodily 468 
function have a central place in their mind as well as in their relationships. 469 
However, it is a body they find it hard to feel and with which they mostly feel 470 
uncomfortable. 471 
• Their approach to the outside world seems to be conflictual, and they seem 472 
to be characterized by introversion and withdrawal. This may lead to 473 
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Table 1. Most common co-morbidities 709 
Co-morbidities Prevalences 
Mood disorders 18.2% - 81% 
Self-reported moodiness 81% 
Depression 5% - 40% 
Bipolar Disorder 7.7% -11.1% 
Dysthymia 4.2% 
  Chronic anxiety 35.7% 
Anxiety  18% - 34% 
Self-reported anxiety 27% 
Generalized Anxiety Disorder 13% - 9.7% 
Anxiety + depression 15% 
Social phobia 4.2% - 27% 
Agoraphobia 2.8% 
  Personality Disorders 2.9% 








Table 2. Descriptive statistics 713 
 PCOS Controls t-test (p values) 
 N M SD N M SD  
Age 59 25.64 5.09 38 25.08 4.81 -0.545 (0.587) 
BMI 59 25.85 6.17 38 21.81 4.32 -3.782 (≤0.001) 
School 
years 







Table 3. TAS-20 718 
 PCOS Controls t-test (p values) 
 M SD M SD 
 
TAS-DIF 50.56 18.49 42.10 16.93 -2.270 (0.025) 
TAS-DDF 54.37 20.33 51.89 21.11 -0.577 (0.565) 
TAS-EOT 42.08 10.44 38.29 11.44 -1.679 (0.096) 
TAS TOT 48.12 12.07 43.03 10.52 -2.131 (0.036) 
Legend: TAS-DIF=Difficulty in Identifying Feelings; TAS-DDF=Difficulty in Describing Feelings; TAS-719 
EOT=Externally Oriented Thinking; TAS TOT= Total Score of Alexithymia 720 
 721 
 722 
Table 4. BUT 723 
 PCOS Controls t-test (p values) 
 M SD M SD 
 
PST 19.59 9.99 14.66 8.82 -2.483 (0.015) 
GSI 1.68 1.03 1.05 0.81 -3.201 (0.002) 




Table 5. MMPI-2 728 
 PCOS Controls t-test (p values) 
 
M DS M DS 
 
L 51.00 8.73 53.16 7.06 1.277 (0.205) 
F 57.49 12.13 48.97 7.39 -3.884 (≤0.001) 
K 46.83 10.39 52.42 10.47 2.579 (0.011) 
Hs 60.91 11.91 53.42 11.05 -3.111 (0.002) 
D 58.39 13.22 50.45 10.18 -3.330 (0.001) 
Hy 54.85 10.62 50.50 8.81 -2.099 (0.038) 
Pd 59.78 8.38 55.92 4.40 -2.969 (0.004) 
Mf 46.24 9.36 47.87 7.65 0.898 (0.371) 
Pa 55.98 10.93 50.37 9.49 -2.596 (0.011) 
Pt 57.19 11.24 51 8.75 -3.034 (0.003) 
Sc 59.12 9.26 54.55 5.44 -3.055 (0.003) 
Ma 50.76 10.18 51.47 9.59 0.343 (0.732) 
Si 54.30 10.36 48.16 10.23 -2.867 (0.005) 
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ANX 57.88 12.34 49.53 9.79 -3.698 (≤0.001) 
FRS 52.17 10.21 47.76 7.61 -2.429 (0.017) 
OBS 55.53 11.82 48.47 8.11 -3.382 (0.001) 
DEP 55.75 10.11 47.68 7.95 -4.153 (≤0.001) 
HEA 60.36 12.28 51.55 10.53 -3.639 (≤0.001) 
BIZ 53.92 10.31 51.40 7.49 -1.301 (0.196) 
ANG 50.76 10.85 49.42 9.63 -0.621 (0.536) 
CYN 53.58 11.36 49.87 10.19 -1.633 (0.106) 
ASP 49.03 7.58 46.84 7.07 -1.427 (0.157) 
TPA 52.56 12.19 51.32 10.77 -0.513 (0.609) 
LSE 54.31 11.35 47.63 8.46 -3.309 (0.001) 
SOD 53.39 11.82 48.13 9.73 -2.287 (0.024) 
FAM 53.68 11.01 47.63 7.78 -3.167 (0.002) 
WRK 55.92 11.23 48.63 8.05 -3.716 (≤0.001) 
TRT 54.73 10.90 48.45 9.22 -2.938 (0.004) 
Fb 55.54 13.12 46.84 6.64 -4.309 (≤0.001) 
TRIN 65.44 10.19 64.32 8.23 -0.571 (0.569) 
VRIN 52.29 10.37 48.47 8.70 -1.881 (0.063) 
MAC 48.76 10.29 49.11 9.70 0.184 (0.870) 
APS 48.17 8.56 47.61 8.08 -0.324 (0.747) 
AAS 55.29 10.32 54.58 11.30 -0.318 (0.751) 
PK 58.07 13.00 48.74 8.98 -4.179 (≤0.001) 
OH 48.88 9.38 51.58 8.57 1.429 (0.156) 
MDS 53.97 12.61 49.21 8.15 -2.256 (0.026) 
Legend: L=Lie; F=Frequency; K=Defensiveness; Hs=Hypochondriasis; D=Depression; Hy=Hysteria; 729 
Pd=Psychopathic Deviation; Mf=Masculinity/Femininity; Pa=Paranoia; Pt=Psychasthenia; Sc=Schizophrenia; 730 
Ma=Hypomania; Si=Social Introversion; ANX=Anxiety; FRS=Fears; OBS=Obsessiveness; DEP=Depression; 731 
HEA=Health Concerns; BIZ=Bizarre Mentation; ANG=Anger; CYN=Cynicism; ASP=Antisocial Practices; 732 
TPA=Type A; LSE=Low Self-Esteem; SOD=Social Discomfort; FAM=Family Problems; Fb=Back F; 733 
TRIN=True Response Inconsistency; VRIN=Variable Response Inconsistency; MAC=MacAndrew Scale; 734 
APS=Addiction Potential Scale; AAS=Addiction Admission Scale; PK=Post-traumatic Stress Disorder; 735 








Table 6. Percentage of elevations in MMPI-2 scales. 742 
 PCOS Controls Chi squares (p values) 
L 1.7% 2.6% 0.100 (0.751) 
F 20.3% 5.3% 4.254 (0.039) 
K 5.1% 13.2% 1.991 (0.158) 
Hs 39.0% 18.4% 4.574 (0.032) 
D 30.5% 7.9% 6.968 (0.008) 
Hy 16.9% 7.9% 1.633 (0.201) 
Pd 22.0% 2.6% 7.045 (0.008) 
Mf 0% 0% Constant 
Pa 16.9% 2.6% 4.713 (0.030) 
Pt 22.0% 7.9% 3.355 (0.067) 
Sc 23.7% 2.6% 7.870 (0.005) 
Ma 10.2% 10.5% 0.003 (0.955) 
Si 16.9% 7.9% 1.633 (0.201) 
ANX 32.2% 10.5% 6.004 (0.014) 
FRS 11.9% 2.6% 2.604 (0.107) 
OBS 16.9% 5.3% 2.912 (0.088) 
DEP 20.3% 0.0% 8.820 (0.003) 
HEA 28.8% 15.8% 2.167 (0.141) 
BIZ 11.9% 2.6% 2.604 (0.107) 
ANG 10.2% 7.9% 0.142 (0.706) 
CYN 15.3% 10.5% 0.445 (0.505) 
ASP 3.4% 2.6% 0.044 (0.833) 
TPA 13.6% 13.2% 0.003 (0.955) 
LSE 18.6% 5.3% 3.566 (0.059) 
SOD 11.9% 5.3% 1.197 (0.274) 
FAM 15.3% 2.6% 3.983 (0.046) 
WRK 20.3% 2.6% 6.244 (0.012) 
TRT 13.6% 5.3% 1.720 (0.190) 
Fb 18.6% 0% 7.991 (0.005) 
TRIN 35.6% 36.8% 0.016 (0.901) 
VRIN 6.8% 2.6% 0.813 (0.367) 
MAC 3.4% 7.9% 0.959 (0.327) 
APS 0% 2.6% 1.569 (0.210) 
AAS 15.3% 18.4% 0.168 (0.682) 
PK 32.2% 7.9% 7.788 (0.005) 
OH 1.7% 5.3% 0.982 (0.322) 
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MDS 23.7% 5.3% 5.722 (0.017) 
 743 
